FDA nod to first oral single-dose treatment for gonorrhea
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership
This launch is part of the company's strategy to expand its nutraceutical portfolio
Dr Srivastava was selected by an expert jury in recognition of her sustained contributions to renewable chemicals, industrial biotechnology and bioprocess innovation
The new powder formulation gives children and adults living with Rett syndrome greater flexibility and choice in dose volume and taste
The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
Clinical trial enrollment has long been a bottleneck in drug development
Subscribe To Our Newsletter & Stay Updated